Technology evaluation: DCVax, Northwest biotherapeutics

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 4, 2002, Pages 403-407

  Knutson, Keith L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CANCER VACCINE; CELL EXTRACT; DCVAX; EPITOPE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RECOMBINANT ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PURIFICATION; BIOTECHNOLOGY; CANCER IMMUNIZATION; CLINICAL TRIAL; DENDRITIC CELL; DRUG CONTRAINDICATION; DRUG METABOLISM; FATIGUE; FEVER; GLIOBLASTOMA; HEADACHE; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; LYMPHADENOPATHY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NAUSEA AND VOMITING; PROSTATE CANCER; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

BRAIN NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS, PHASE III; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MALE; PROSTATIC NEOPLASMS;

MYCOBACTERIUM BOVIS BCG;

EID: 0036705263     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Nair SK, Snyder D, Rouse BT, Gilboa E INT J CANCER 1997 70 6 706-715
2. NWBio options kidney cancer technology. Northwest Biotherapeutics Inc PRESS RELEASE 2000 July 11
3. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB et al NAT MED 1995 1 12 1297-1302
4. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD J EXP MED 1996 183 1 283-287
5. Northwest Biotherapeutics Inc to initiate phase I lung cancer trial. Northwest Biotherapeutics Inc PRESS RELEASE 2002 February 28
6. Northwest Biotherapeutics Inc announces fourth-quarter and full-year financial results. Northwest Biotherapeutics Inc PRESS RELEASE 2002 March 21
7. Immunotherapy for androgen independent prostate cancer: Results of a phase I trial with a tumor vaccine of autologous dendritic cells loaded with r-PSMA (DCVax™-Prostate). Assikis VJ, Elgamal AA, Tu SM, Daliani D, Pagliaro L, Logothetis C, Papandreou C PROC ANNU MEET AM ASSOC CANCER RES 2002 43 Abs 3352
8. Maturation of dendritic cells for cancer immunotherapy, using inactivated BCG and interferon-γ. Induction of a vigorous Th1 response. Trimble L, Shankar G, Kelley H, Minderhout V, Bosch ML PROC ANNU MEET AM ASSOC CANCER RES 2002 43 Abs 3368
9. Dendritic cell vaccine presenting eluted tumor antigens for treatment of patients with glioblastoma multiforme: Interim phase I trial results of DCVax-Brain. Liau L, Salgaller M, Kiertscher S, Roth M, Cloughesy T, Mischel P, Martin N, Becker D PROC ANNU MEET AM ASSOC CANCER RES 2002 93 LB-130
10. Northwest Biotherapeutics Inc to report prostate cancer product characterization and new clinical data. Northwest Biotherapeutics Inc PRESS RELEASE 2002 May 08
11. Northwest Biotherapeutics Inc. INT BIOTECH CONV & EXHIB 2002 Suppl June 09-12
12. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI J IMMUNOL 2001 166 1 678-689
13. Prostate. Northwest Biotherapeutics Inc COMPANY WORLD WIDE WEB SITE 2002 July 01
14. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH CANCER 1998 83 11 2259-2269
15. Monitoring responses of prostate cancer patients. vaccinated with prostate-specific membrane antigen (PSMA) protein-loaded dendritic cells (DC) in a phase I/II clinical trial. Shankar G, Kelley H, Lodge A et al PROC ANNU MEET AM ASSOC CANCER RES 2001 42 Abs 142
16. Brain. Northwest Biotherapeutics Inc COMPANY WORLD WIDE WEB SITE 2002 July 01
17. Role of dendritic cells in the induction and maintenance of autoimmune diseases. Ludewig B, Odermatt B, Ochsenbein AF, Zinkernagel RM, Hengartner H IMMUNOL REV 1999 169 45-54
18. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA J IMMUNOTHER 2001 24 4 363-373
19. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369- 377, results in short-lived peptide-specific immunity. Knutson KL, Schiffman K, Cheever MA, Disis ML CLIN CANCER RES 2002 8 5 1014-1018
20. Immunization with a HER-2/neu helper peptide vaccine generates HER- 2/neu CD8 T-cell immunity in cancer patients. Knutson KL, Schiffman K, Disis ML J CLIN INVEST 2001 107 4 477-484
21. Active immunization against cancer with dendritic cells: The near future. Steinman RM, Dhodapkar M INT J CANCER 2001 94 4 459-473
22. Dendritic cells injected via different routes induce immunity in cancer patients. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG J IMMUNOL 2001 166 6 4254-4259
23. Fluorine-18 labeled mouse bone marrow-derived dendritic cells can be detected in vivo by high resolution projection imaging. Olasz EB, Lang L, Seidel J, Green MV, Eckelman WC, Katz SI J IMMUNOL METHODS 2002 260 1-2 137-148
24. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: Implications for dendritic cell-based vaccines. Barratt Boyes SM, Zimmer MI, Harshyne LA, Meyer EM, Watkins SC, Capuano S, Murphey Corb M, Falo LD, Donnenberg AD J IMMUNOL 2000 164 5 2487-2495
25. Regulation of CD1d expression by murine tumor cells: Escape from immunosurveillance or alternate target molecules? Fieldler T, Walter W, Reichert TE, Maeurer MJ INT J CANCER 2002 98 3 389-397
26. Immunosuppressive factors: Role in cancer development and progression. Botti C, Seregni E, Ferrari L, Martinetti A, Bombardieri E INT J BIOL MARKERS 1998 13 2 51-69
27. Lung. Northwest Biotherapeutics Inc COMPANY WORLD WIDE WEB SITE 2002 July 01